InvestorsHub Logo
Followers 67
Posts 16221
Boards Moderated 2
Alias Born 02/14/2011

Re: ECole post# 80

Wednesday, 07/17/2013 8:45:29 AM

Wednesday, July 17, 2013 8:45:29 AM

Post# of 110
8:24 AM UBS thinks data from a Phase III study will "suggest a greater magnitude of overall survival benefit" for Medivation's (MDVN) Xtandi than for Janssen's (JNJ) Zytiga. Analyst Matthew Roden upgrades MDVN to Buy and hikes his price target to $74 from $59